NEWS & EVENTS

Latest news and upcoming events

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
10 Nov 2022

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

Upcoming events

  • Jefferies London Healthcare Conference
    14 - 17 November 2022,
    London

    download

  • Ship2B Impact Forum
    30 November 2022,
    Barcelona

    download

  • BIO-EUROPE 2022
    24 - 26 October 2022,
    Leipzig

    download
SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa<
01 Dec 2022

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

First safety data expected in 2023 with full read-out expected in 2025
Aura Biosciences Announces Pricing of Public Offering of Common Stock<
01 Dec 2022

Aura Biosciences Announces Pricing of Public Offering of Common Stock

The offering is expected to close on or about December 5, 2022, subject to customary closing conditions.
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension<
16 Nov 2022

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

Key clinical data from Target-HTN demonstrated clinically meaningful efficacy in the treatment of patients with uncontrolled and resistant hypertension
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage<
11 Nov 2022

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage

The trial will evaluate the efficacy and safety of belzupacap sarotalocan (bel-sar) with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft<
11 Nov 2022

Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

The aXess graft turns into a living blood vessel, promising an unprecedented, immediate and durable solution for hemodialysis patients
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe<
10 Nov 2022

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

Significant double-digit upfront payment in addition to milestone payments and development funding totaling up to EUR 258 million in the aggregate
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update<
09 Nov 2022

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients<
08 Nov 2022

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseases
Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine<
02 Nov 2022

Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine

The study achieved its primary and secondary endpoints of safety, tolerability and immunogenicity.
AM-Pharma provides business update and outcome of pre-planned interim futility analysis of phase 3 REVIVAL study<
20 Oct 2022

AM-Pharma provides business update and outcome of pre-planned interim futility analysis of phase 3 REVIVAL study

Clear path forward for ilofotase alfa as potential treatment in acute kidney injury.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.